I’ve spent over 15 years on work related to cancer treatments and drug development, and in that time it has occurred to me that drug discovery can be very similar to team bicycle racing. Both require endurance, perseverance, balance, the ability to overcome dramatic obstacles, and trust in your colleagues. There are days when slogging through the process may appear tedious to outsiders, but fighting through the pain and frustration is necessary to make true progress. And while the team captain drives the overall process, he knows that the heart of the matter is the teamwork that makes the journey successful.
As the President and CEO of H3 Biomedicine, I am ultimately responsible for our mission to generate novel small-molecule drugs for some of the most difficult-to-treat cancer types. It is my responsibility to lead my team, steering the sophisticated, technical tactics my colleagues ply day after day to achieve our end result: innovative treatments for cancer, and hope for patients who need better options.
As our understanding of cancer drivers evolves, it brings with it both challenges and answers. There are countless unmet medical needs, and our industry has just barely begun to leverage the potential of genomic insights. At H3, our vision of cancer research and drug development is based on teamwork, collaboration and world-class science.
With our outstanding collaborators and team of employees, H3 has built a broad foundation of expertise practically unparalleled in our industry. Our scientists and technicians are successfully applying bioinformatics, tumor biology, and discovery and medicinal chemistry to accelerate our drug discovery process. We leverage insights into the genomic characteristics of cancer to advance our efforts in many directions, from deciphering drivers of cancer to understanding misregulated splicing, to the identification of unique cancer antigens that aid immuno-oncology approaches.
Our collaborative approach has translated these findings into a fast-moving, genomic-based drug discovery engine; we have identified a lead candidate and commenced IND-enabling studies in less than two years—a remarkable timeframe for a novel drug target.
As a CEO, I am proud of our unique collaborative culture and the ability to work in state-of-the-art laboratories and offices. Being able to conduct scientific research in our top-notch facilities in the heart of the Cambridge, Massachusetts biotech area not only puts us into close proximity to our two scientific founders, it also enables us to attract top scientific talent to join our mission and to bring additional jobs to this region.
Today we are at one of the most exciting moments in cancer research and drug discovery at one of the most exciting young biopharmaceutical companies conducting research in this space. It is my job to keep the team moving, and to make sure we never lose sight of the humanity that underscores our progress: the challenge of cancer, and the patients we are ultimately fighting for. This goal is symbolized by our name, H3: HUMAN, HEALTH & HOPE.